The National Comprehensive Cancer Network®  (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

 

Kalaycio is a graduate of Lincoln High School. 

 

“The exemplary leadership from our board of directors is invaluable as NCCN defines and advances high-quality, high-value, patient-centered cancer care around the world,” said NCCN  Chief Executive Officer Crystal S. Denlinger, MD, who took on the role in October of 2023. “Their steady guidance during a transitional time helps us maintain our highly trusted, continuously updated, evidence-based, expert consensus recommendations for cancer care, which were accessed more than 15 million times in 2023 alone. I look forward to working even more closely with Matt and Chris and relying on the substantial expertise, caring, and leadership they bring to these positions.”

 

Dr. Kalaycio is a leading expert in hematology and medical oncology who specializes in the treatment of leukemia, hematopoietic cell transplantation, and CAR T-Cell therapy. He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. 

 

"NCCN is committed to ensuring that all cancer patients receive the latest evidence-based treatment options by not only informing healthcare providers of available treatments, but also offering education and support to the patients and their caregivers,” said Dr. Kalaycio. “As 

I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization’s mission." 

 

Dr. Lieu is an Associate Professor; Co-Director, Gastrointestinal Medical Oncology; and Associate Director for Clinical Research for the University of Colorado Cancer Center.